Cefic-lri Programme | European Chemical Industry Council

EMSG57-LAKIND: Endocrine disruptors and obesity, diabetes and heart disease: State of the science and biological plausibility

Principal Investigator

LaKind Associates, LLC
106 Oakdale Avenue
Catonsville, Maryland USA 21228
Dr. Judy LaKind
Tel: +1 410.788.8639
Fax: +1 410.788.8639


Michael Goodman, MD, Department of Epidemiology, Rollins School of Public Health, Emory University, USA
Donald R. Mattison, MD, Risk Sciences International, USA


This project builds on (i) the lessons learned from the recently completed work on methodologic issues affecting epidemiologic research on BPA and (ii) the findings of the project (conducted under Cefic-LRI EMSG54) related to the importance of harmonization of epidemiologic methods for weight-of-evidence assessment. This relevant experience will be used to examine in detail the studies of endocrine disruptors in relation to obesity, diabetes and heart disease.

This project addresses the RfP pbjectives in three phases that will bring a fresh perspective to the complex and important issue of exogenous endocrine disruptors as determinants of human health outcomes:

Phase 1: Critical literature review and meta-analysis with 1 or 2 exemplar chemicals: Assessment of consistency across results and sufficiency of evidence for a given chemical.

Phase 2: Critical examination of methodologic issues affecting epidemiologic research on endocrine-active environmental chemicals: Assessment of the relation between study methods and reported findings.

Phase 3: Evaluation of biological plausibility: Assessment of epidemiological and clinical trial findings with chemical and pharmacologic mechanisms of action using exemplar drugs.

Related Publications

Mattison et al. Pharmaco- and toxicokinetics of selected exogenous and endogenous estrogens: A review of the data and identification of knowledge gaps. Critical Reviews in Toxicology. 2014. Early Online. 1-29.

Please click here for further information.

Timeline: January 2013 > July 2013

LRI funding: $ 150,000

Cefic-Lri Programme Responsible Care

© Copyright 2017 Cefic | European Chemical Industry Council. All rights reserved | Terms and Conditions of Use